CGTX Cognition Therapeutics, Inc.
Price Chart
Executive Summary
Cognition Therapeutics announced its CEO will present at the Jefferies Global Healthcare Conference (June 4) and H.C. Wainwright Neuro Perspectives Summit (on-demand from June 15) to provide updates on the planned registration program for zervimesine in DLB psychosis. No financial data was disclosed; the press release is a routine corporate update.
Actionable Insight
Monitor the CEO presentations for any updates on the DLB psychosis registration program, but no immediate trading catalyst is expected from this announcement alone.
Key Facts
- CEO Lisa Ricciardi to present at 2026 Jefferies Global Healthcare Conference on June 4 at 1:25 p.m. ET.
- CEO to present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on-demand beginning June 15 at 8:00 a.m. ET.
- Company plans to advance zervimesine (CT1812) into a late-stage clinical trial for DLB psychosis following positive Phase 2 SHIMMER study results.
- No new financial or clinical data released in this announcement.
Financial Impact
No financial impact from this press release.
Risk Factors
- Clinical trial risks for zervimesine in DLB psychosis.
- Regulatory uncertainties regarding the registration program.
- Dependence on future financing for clinical development.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304237 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
1d ago
|
8-K
| $1.41 awaiting T+1 | awaiting T+1 | — | $1.27 (−9.57%) |
|
Jun 1, 2026
4d ago
|
Press Release
| $1.25 $1.35 | ▲ +8.00% | ▲ +7.86% | $1.27 (+2.00%) |
|
May 21, 2026
15d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
May 14, 2026
22d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
May 7, 2026
28d ago
|
8-K
| $1.21 $1.18 | ▼ −2.48% | ▼ −2.71% | $1.27 (+5.37%) |
|
Apr 16, 2026
7w ago
|
Insider Cluster
| $1.11 $1.19 | ▲ +7.21% | ▲ +5.99% | $1.27 (+14.86%) |
|
Mar 26, 2026
10w ago
|
Press Release
| $1.08 $0.7300 | ▼ −32.41% | ▼ −30.73% | $1.27 (+18.06%) |
|
Mar 23, 2026
10w ago
|
Press Release
| $1.13 $1.10 | ▼ −2.65% | ▼ −2.30% | $1.27 (+12.83%) |
|
Mar 17, 2026
11w ago
|
Press Release
| $1.15 $1.10 | ▼ −4.35% | ▼ −2.95% | $1.27 (+10.87%) |
|
Mar 2, 2026
13w ago
|
Press Release
| $1.06 $1.02 | ▼ −3.77% | ▼ −2.86% | $1.27 (+20.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access